<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03495297</url>
  </required_header>
  <id_info>
    <org_study_id>NL64634_018_18</org_study_id>
    <nct_id>NCT03495297</nct_id>
  </id_info>
  <brief_title>A Randomised Trial of S-ICD Implantation With and Without Defibrillation Testing</brief_title>
  <acronym>PRAETORIAN-DFT</acronym>
  <official_title>A Prospective Randomised CompArative Trial of SubcutanEous ImplanTable CardiOverter-DefibrillatoR ImplANtation With and Without DeFibrillation Testing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the hypothesis that implantation of a subcutaneous implantable&#xD;
      cardioverter defibrillator (S-ICD) without performing a defibrillation test is non-inferior&#xD;
      to S-ICD implant with a defibrillation test with regards to the primary endpoint failed first&#xD;
      shock in a spontaneous arrhythmia episode when implant position is confirmed with PRAETORIAN&#xD;
      score.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Implantable Cardioverter Defibrillator (ICD) implant improves survival in patients with a&#xD;
      higher risk for sudden cardiac death. There are 2 types of ICD available; transvenous ICD&#xD;
      (TV-ICD) and subcutaneous ICD (S-ICD). During ICD implant, defibrillation testing (DFT) is&#xD;
      performed to test functionality of the device. However, DFT can be associated with&#xD;
      complications such as inability to convert, complications arising from general anaesthesia,&#xD;
      prolonged resuscitation, stroke and death. Whereas DFT may be associated with complications,&#xD;
      the benefit of DFT is debated as literature shows there is only a modest average effect of&#xD;
      DFT, if any, on mortality, shock efficacy or safety. Recently it was shown in a randomized&#xD;
      controlled trial called 'SIMPLE' that routine defibrillation testing of TV-ICDs at the time&#xD;
      of implant does not improve shock efficacy or reduce arrhythmic death. For S-ICD there is&#xD;
      only limited data available of the effect of DFT on S-ICD efficacy. Data have however shown&#xD;
      that the conversion efficacy of the S-ICD is comparable to TV-ICD.&#xD;
&#xD;
      DFT is currently performed in standard S-ICD implants, but is omitted in specific cases.&#xD;
      However, an alternative method to evaluate the correct position may be desired when omitting&#xD;
      DFT. The PRAETORIAN Score is developed using computer modelling data on factors influencing&#xD;
      defibrillation thresholds. The PRAETORIAN score represents the chance of a patient having an&#xD;
      elevated defibrillation threshold and consequently failing a DFT or conversion of a&#xD;
      spontaneous arrhythmia episode. The score was retrospectively validated in two studies with&#xD;
      180 and 321 patients.&#xD;
&#xD;
      It was reported that most S-ICD implants are performed under general anesthesia, however&#xD;
      other anesthesia protocols are used as well. One of the most predominant factors to use&#xD;
      general anesthesia is the performance of the DFT. If this is omitted, other anesthesia&#xD;
      protocols may be a good option for many patients as well.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2018</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failed first appropriate shock in a spontaneous episode</measure>
    <time_frame>40 months</time_frame>
    <description>Number of patients having experiences a failed first appropriate shock in a spontaneous arrhythmia episode</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DFT related complications</measure>
    <time_frame>24 hours or 30 days</time_frame>
    <description>Number of patients experiencing DFT related complications occurring within 24h or 30 days after DFT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRAETORIAN Score</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Implant position will be scored using the PRAETORIAN score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain post implant</measure>
    <time_frame>1-4 hours post implant</time_frame>
    <description>Pain score measured with McGill questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appropriate ICD therapy</measure>
    <time_frame>40 months</time_frame>
    <description>Shocks given for VT or VF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inappropriate ICD therapy</measure>
    <time_frame>40 months</time_frame>
    <description>Shocks given for anything else than VT or VF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall DFT conversion success</measure>
    <time_frame>40 months</time_frame>
    <description>The percentage of patients with at least one induced episode teminated by an S-ICD shock within five seconds post shock delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successful DFT</measure>
    <time_frame>40 months</time_frame>
    <description>A successful DFT is defined as conversion to SR or AF in less than 5 seconds from appropriate shock delivery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to therapy</measure>
    <time_frame>40 months</time_frame>
    <description>Time to therapy is the time between the start of VT or VF in a treated episode until the first shock in seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to succesful therapy</measure>
    <time_frame>40 months</time_frame>
    <description>Time to successful therapy is the time between the start of VT or VF until the first successful shock.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shock efficacy</measure>
    <time_frame>40 months</time_frame>
    <description>Percentage of appropriate shocks that was successfull</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion efficacy within 5 shocks in spontaneous episodes</measure>
    <time_frame>40 months</time_frame>
    <description>Conversion efficacy within 5 shocks in spontaneous episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>S-ICD related complications</measure>
    <time_frame>40 months</time_frame>
    <description>S-ICD related complications requiring invasive intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE post DFT</measure>
    <time_frame>30 days</time_frame>
    <description>Number of Major Adverse Cardiac Events after DFT procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac (pre-)syncope</measure>
    <time_frame>40 months</time_frame>
    <description>Number of episodes of cardiac (pre-)syncope</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac decompensation</measure>
    <time_frame>40 months</time_frame>
    <description>Number of episodes of cardiac decompensation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>40 months</time_frame>
    <description>All cause mortality; arrhythmic death; cardiovascular death; unexplained death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>40 months</time_frame>
    <description>Length of hospitalization post implant (nights)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device or lead repositioning</measure>
    <time_frame>40 months</time_frame>
    <description>Number of procedures for device or lead repositioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICD related infection</measure>
    <time_frame>40 months</time_frame>
    <description>Number of infections related to implanted ICD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite complications 30 days after implant</measure>
    <time_frame>30 days</time_frame>
    <description>Number of patients experiencing complications occurring within 30 days after implant</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">965</enrollment>
  <condition>Ventricular Arrythmia</condition>
  <arm_group>
    <arm_group_label>S-ICD Implant with defibrillation test</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients undergoing de novo S-ICD implantation including induction of VF and defibrillation testing post-implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S-ICD Implant without defibrillation test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing de novo S-ICD implantation without induction of VF and defibrillation testing post-implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ommitence of defibrillation testing</intervention_name>
    <description>Induction of a ventricular arrhythmia to test proper arrhythmia detection and termination by the implanted device is omitted</description>
    <arm_group_label>S-ICD Implant without defibrillation test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who meet current guidelines for ICD therapy and intent to undergo a de novo&#xD;
             implant procedure for an S-ICD&#xD;
&#xD;
          -  Patients must pass S-ICD screening per local routine&#xD;
&#xD;
          -  Patients over 18 years of age, willing and capable to give informed consent&#xD;
&#xD;
          -  Patients must be willing and capable of complying to follow up visits&#xD;
&#xD;
          -  Patient must be eligible for either DFT strategy per physician discretion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with a life expectancy shorter than 12 months due to any medical condition&#xD;
&#xD;
          -  Patients known to be pregnant&#xD;
&#xD;
          -  Patients with intracardiac thrombus&#xD;
&#xD;
          -  Patients with atrial fibrillation without appropriate anticoagulation&#xD;
&#xD;
          -  Patients likely to undergo heart transplant within 12 months&#xD;
&#xD;
          -  Patients with LVAD&#xD;
&#xD;
          -  Patients with other contra-indications for DFT per physician's discretion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reinoud E Knops, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reinoud E Knops, MD, PhD</last_name>
    <phone>+31205666555</phone>
    <email>r.e.knops@amc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lonneke Schats - Smeding, PhD</last_name>
    <phone>+31205665424</phone>
    <email>l.smeding@amc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Adventh Health System</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leann Goodwin</last_name>
      <email>Leann.Goodwin@AdventHealth.com</email>
    </contact>
    <investigator>
      <last_name>Naushad Shaik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Nelson</last_name>
      <email>jessica.nelson@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Mikhael F El-Chami, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CorVita Science Foundation</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin C Burke, DO</last_name>
      <email>mburke@corvitahealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Englewood Hospital and Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Shaji</last_name>
      <email>Elizabeth.Shaji@EHMCHealth.org</email>
    </contact>
    <investigator>
      <last_name>Dmitry Nemirovsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Beth Israel</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Hanon, MD</last_name>
      <email>samuel.hanon@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Samuel Hanon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinaï</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc A Miller, MD</last_name>
      <email>marc.miller@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Marc A Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erlanger Health System</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Harris</last_name>
      <email>Geneva.Harris@erlanger.org</email>
    </contact>
    <investigator>
      <last_name>Harish Manyam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Kliniken</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Fürst</last_name>
      <email>k.fuerst@asklepios.com</email>
    </contact>
    <investigator>
      <last_name>Nils Gosau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hendrik Bonnemeier, MD</last_name>
      <email>hendrik.bonnemeier@uksh.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antje Maass</last_name>
      <email>antje.maass@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Roland R Tilz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Kuschyk, MD</last_name>
      <email>Juergen.Kuschyk@umm.de</email>
    </contact>
    <contact_backup>
      <last_name>Boris Rudic, MD</last_name>
      <email>boris.rudic@umm.de</email>
    </contact_backup>
    <investigator>
      <last_name>Jürgen Kuschyk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Octavian Maniuc, MD</last_name>
      <email>Maniuc_O@ukw.de</email>
    </contact>
    <investigator>
      <last_name>Peter Nordbeck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flevoziekenhuis</name>
      <address>
        <city>Almere</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Bijsterveld, MD, PhD</last_name>
      <email>NBijsterveld@Flevoziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Nick Bijsterveld, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L V Vertelman, MSc</last_name>
      <email>l.v.vertelman@amsterdamumc.nl</email>
    </contact>
    <investigator>
      <last_name>R E Knops, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonas S.S.G. de Jong, MD, PhD</last_name>
      <email>J.S.S.G.deJong@olvg.nl</email>
    </contact>
    <investigator>
      <last_name>Jonas S.S.G. de Jong, Md, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Ziekenhuis</name>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Selina Vlieger</last_name>
      <email>S.Vlieger@asz.nl</email>
    </contact>
    <investigator>
      <last_name>Leon J.P.M. van Woerkens, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria van Eijck</last_name>
      <email>maria.v.eijck@catharinaziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Frank A.L.E Bracke, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander M. Maass, MD, PhD</last_name>
      <email>a.h.maass@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Alexander M. Maass, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spaarne Gastheuis</name>
      <address>
        <city>Haarlem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Kalkman</last_name>
      <email>cardioreserach@spaarnagasthuis.nl</email>
    </contact>
    <investigator>
      <last_name>Dirk Jan van Doorn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fleur A.E. Borger van der Burg, MD, PhD</last_name>
      <email>a.e.borgervanderburg@znb.nl</email>
    </contact>
    <investigator>
      <last_name>Fleur A.E. Borger van der Burg, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucas V.A. Boersma, MD, PhD</last_name>
      <email>l.boersma@antoniusziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Lucas V.A. Boersma, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Canisius Wilhelmina Ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Elders</last_name>
      <email>j.elders@cwz.nl</email>
    </contact>
    <investigator>
      <last_name>H MM Alhashimi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter-Paul H.M. Delnoy, MD, PhD</last_name>
      <email>p.p.h.m.delnoy@isala.nl</email>
    </contact>
    <investigator>
      <last_name>Peter-Paul H.M. Delnoy, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Basildon and Thurrock Univerity Hospital NHS Foundation Trust</name>
      <address>
        <city>Basildon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duncan C Field, MD</last_name>
      <email>Duncan.Field@colchesterhospital.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Duncan Field, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blackpool Victoria Hospital NHS Foundation Trust</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Cassidy, MD</last_name>
      <email>christopher.cassidy2@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Christopher Cassidy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Papworth Hospital NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Martin, MD</last_name>
      <email>claire.martin22@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Claire Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart and Chest Hospital NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay D.J. Wright, MD</last_name>
      <email>David.Wright@lhch.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Jay Wright, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust of the Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>ÉC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hakam Abbass</last_name>
      <email>hakam.abbass@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Pier Lambiase, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manchester Heart Center, Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Phillips</last_name>
      <email>Hannah.Phillips@mft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Amir Zaidi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Webster</last_name>
      <email>David.Webster@ouh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Tim R Betts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals NHS Foundation Trust, Northern General Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nigel Lewis, MD</last_name>
      <email>nigel.lewis1@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Nigel Lewis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Wolverhampton NHS Trust, the New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Smallwood</last_name>
      <email>andy.smallwood@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Anita Arya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Quast ABE, Baalman SWE, Betts TR, Boersma LVA, Bonnemeier H, Boveda S, Brouwer TF, Burke MC, Delnoy PPHM, El-Chami M, Kuschyk J, Lambiase P, Marquie C, Miller MA, Smeding L, Wilde AAM, Knops RE. Rationale and design of the PRAETORIAN-DFT trial: A prospective randomized CompArative trial of SubcutanEous ImplanTable CardiOverter-DefibrillatoR ImplANtation with and without DeFibrillation testing. Am Heart J. 2019 Aug;214:167-174. doi: 10.1016/j.ahj.2019.05.002. Epub 2019 May 16.</citation>
    <PMID>31220775</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 23, 2018</study_first_submitted>
  <study_first_submitted_qc>April 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2018</study_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>R.E. Knops</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>subcutaneous implantable cardioverter defibrillator</keyword>
  <keyword>Defibrillation testing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

